Procoagulant profile in patients with immune thrombocytopenia

Br J Haematol. 2016 Dec;175(5):925-934. doi: 10.1111/bjh.14412. Epub 2016 Oct 21.

Abstract

Despite their low platelet count some immune thrombocytopenia (ITP) patients seldom bleed, indicating the presence of factors to compensate thrombocytopenia. Moreover, ITP patients may have an increased risk for thrombosis. These facts suggest the presence of procoagulant mechanisms that have not been clarified yet. The aim of this study was to identify these possible factors. Moreover, the utility of rotational thromboelastometry (ROTEM® ) to test haemostasis in these patients was also evaluated. Patients with ITP presented a procoagulant profile due to an increased amount of platelet- and red cell-microparticles, an increased resistance to protein C and the formation of a clot more resistant to fibrinolysis due to augmented levels of plasminogen activator inhibitor-1, which might reflect an endothelial damage/activation in ITP patients. Despite increased maximum clot firmness and reduced lysis, ROTEM® profiles showed a prolonged clotting time that might rely on the presence of anti-platelet antibodies as suggested by the increased lagtime in thrombin generation test caused by plasma from ITP patients on platelets from healthy controls. These results indicate the need to individualize therapeutic treatment for ITP patients, considering their procoagulant profile and the presence of concomitant risk factors. Moreover, ROTEM® appeared to be useful for evaluating haemostasis in ITP patients.

Keywords: fibrinolysis; immune thrombocytopenia; microparticles; thrombin generation; thromboelastometry.

MeSH terms

  • Adult
  • Aged
  • Blood Coagulation Tests
  • Blood Coagulation*
  • Blood Platelets / pathology
  • Cell-Derived Microparticles / pathology
  • Female
  • Hemostasis*
  • Humans
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1
  • Purpura, Thrombocytopenic, Idiopathic / blood*
  • Purpura, Thrombocytopenic, Idiopathic / complications
  • Thrombelastography / methods*

Substances

  • Plasminogen Activator Inhibitor 1